Response and actions taken with respect to the reviewer comments for:


No. s41467-019-11014-1

Title: " A zwitterionic near-infrared fluorophore for real-time ureter identification during laparoscopic abdominopelvic surgery"

Author(s): Surname, First name; Surname, First Name; [τ](https://www.douban.com/people/obafgkm/)\*

上面标题部分请修改论文编号（No.）、标题（Title）和作者。

Reviewer意见需要完整copy&paste到这个文档中，不可遗漏。需要分段列出，每一条针对性的回应。Paste到该文档之后，在word的“开始”——“样式”选项组将其样式改为“1\_reviewer”。



针对每一条comment给出response和action，将其样式改为“2\_Response/Action”。如果action中包括了对论文文稿的修改，应将修改部分paste到此文档，并将其样式改为“3\_change\_made\_in\_draft”。

下文为范例，可以直接替换其中内容部分。切记关闭中文输入法，不可引入任何中文字符。

在文档完成之后，请删除此text box。建议请前往[豆瓣讨论](https://www.douban.com/people/obafgkm/status/2559597492/)。

Update1：Comments from [hydralisk扎克](https://www.douban.com/people/42130143)和[云飞扬](https://www.douban.com/people/30203603)：

1. 字体也可以用 Times New Roman/Helvetica；……提到修改版的内容的时候最好加上 in Page XXX, Line YYY in the highlighted revised version，因为会有两个修改版，一个clean黑白版，一个高亮版（会把原稿的一些部分划掉），页码和行数往往不一样。

2. 如果不习惯黄底标注，可以考虑在response里面说在第几页第几行删了什么或者加了什么，双引号update过后的内容；或者考虑用红色字体（非高亮）的。

We would like to thank the reviewers for their insightful comments. Our responses and actions taken are detailed below. The changes are highlighted in yellow in the manuscript file uploaded as supporting information for review.

Reviewer 1

4. AEs are not reported and should be included in Table 1. The section on “clinical studies: safety and tolerability” appears to be contradictory. In one sentence, it is stated that no subject experienced an adverse event (AE) – yet in the next sentence, 7 out of 16 (that’s almost 50%) reported a total of 10 AEs. These should be reported in the literature, at least in Table 1. The last sentence of the contribution that applauds safety of ZW800-1 isn’t consistent with the adverse events that occurred, but not reported in a Table.

Response: These are excellent points.

**Actions**: We have now added **Supplementary Table 2. Overview of adverse events**, which contains a very detailed listing of all adverse events encountered during the Phase 1 and Phase 2 clinical trials. The table is also referenced in the Results section ‘Clinical studies: safety and tolerability’ in Page XXX, Line YYY in the highlighted revised version:

“A detailed listing of reported AEs is provided in Supplementary Table 2.”

In addition, we have revised the noted sentence as follows in Page XXX, Line YYY in the highlighted revised version:

“There were no serious adverse events attributed to ZW800-1. Those AEs reported during the trial were mild or moderate, none required interruption of the trial, and all resolved without sequelae.”